198 related articles for article (PubMed ID: 23687287)
1. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.
Gupta RK; Wainberg MA; Brun-Vezinet F; Gatell JM; Albert J; Sönnerborg A; Nachega JB
J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S101-6. PubMed ID: 23687287
[TBL] [Abstract][Full Text] [Related]
2. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
Li J; Dufrene SL; Okulicz JF
Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
Dolling D; Phillips AN; Delpech V; Pillay D; Cane PA; Crook AM; Shepherd J; Fearnhill E; Hill T; Dunn D; ;
HIV Med; 2012 May; 13(5):309-14. PubMed ID: 22151684
[TBL] [Abstract][Full Text] [Related]
5. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Myers GM; Mayer KH
AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
[TBL] [Abstract][Full Text] [Related]
6. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
[TBL] [Abstract][Full Text] [Related]
7. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
Baeten JM; Haberer JE; Liu AY; Sista N
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
[TBL] [Abstract][Full Text] [Related]
8. HIV preexposure prophylaxis: new data and potential use.
Celum CL
Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
[TBL] [Abstract][Full Text] [Related]
9. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
10. Oral antiretroviral chemoprophylaxis: current status.
Baeten J; Celum C
Curr Opin HIV AIDS; 2012 Nov; 7(6):514-9. PubMed ID: 22964886
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
12. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
Betancor G; Garriga C; Puertas MC; Nevot M; Anta L; Blanco JL; Pérez-Elías MJ; de Mendoza C; Martínez MA; Martinez-Picado J; Menéndez-Arias L; ; Iribarren JA; Caballero E; Ribera E; Llibre JM; Clotet B; Jaén A; Dalmau D; Gatel JM; Peraire J; Vidal F; Vidal C; Riera M; Córdoba J; López Aldeguer J; Galindo MJ; Gutiérrez F; Álvarez M; García F; Pérez-Romero P; Viciana P; Leal M; Palomares JC; Pineda JA; Viciana I; Santos J; Rodríguez P; Gómez Sirvent JL; Gutiérrez C; Moreno S; Pérez-Olmeda M; Alcamí J; Rodríguez C; del Romero J; Cañizares A; Pedreira J; Miralles C; Ocampo A; Morano L; Aguilera A; Garrido C; Manuzza G; Poveda E; Soriano V
Retrovirology; 2012 Aug; 9():68. PubMed ID: 22889300
[TBL] [Abstract][Full Text] [Related]
13. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR
PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
[TBL] [Abstract][Full Text] [Related]
14. [HIV therapy and adherence].
Kuhlmann B
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():62-3. PubMed ID: 19024920
[No Abstract] [Full Text] [Related]
15. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
Grant RM; Liegler T; Defechereux P; Kashuba AD; Taylor D; Abdel-Mohsen M; Deese J; Fransen K; De Baetselier I; Crucitti T; Bentley G; Agingu W; Ahmed K; Damme LV
AIDS; 2015 Jan; 29(3):331-7. PubMed ID: 25503265
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Okwundu CI; Uthman OA; Okoromah CA
Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
[TBL] [Abstract][Full Text] [Related]
17. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB
Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402
[TBL] [Abstract][Full Text] [Related]
18. [Pre-exposure prophylaxis for HIV transmission? No, unless].
Boeke AJ; Heijnen AM
Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
[TBL] [Abstract][Full Text] [Related]
19. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
Corneli AL; Deese J; Wang M; Taylor D; Ahmed K; Agot K; Lombaard J; Manongi R; Kapiga S; Kashuba A; Van Damme L;
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):324-31. PubMed ID: 25157647
[TBL] [Abstract][Full Text] [Related]
20. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
Krakower D; Mayer KH
Ann Intern Med; 2012 Oct; 157(7):490-7. PubMed ID: 22821365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
